Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORCE: Sorafenib in Resected Primary Renal Cell Carcinoma
NCT00492258Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jun 2007
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Placebo 3 Years, Sorafenib 1y -> Placebo 2y and Sorafenib 3 Years (3 arms). Primary endpoint: Disease-Free Survival. Started Jun 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00492258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492258.